Compounds > buparvaquone
Page last updated: 2024-08-25

buparvaquone and Disease Models, Animal

buparvaquone has been researched along with Disease Models, Animal in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (60.00)24.3611
2020's2 (40.00)2.80

Authors

AuthorsStudies
Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV1
Abdel Shafi, IR; Abdel-Aal, AA; Afife, AA; Esmat, M; Fahmy, MEA; Hassan, SI; Shaheen, HAA; Shalaby, MA1
Aguado-Martínez, A; Barrett, LK; Choi, R; Ferre, I; Hemphill, A; Hulverson, MA; Maly, DJ; McCloskey, MC; Moreno-Gonzalo, J; Müller, J; Ojo, KK; Ortega-Mora, LM; Van Voorhis, W1
Bolás-Fernández, F; Dea-Ayuela, MA; Lalatsa, A; Mauger, M; Serrano, DR; Smith, L1
Colombo, FA; Pereira-Chioccola, VL; Reimão, JQ; Tempone, AG1

Other Studies

5 other study(ies) available for buparvaquone and Disease Models, Animal

ArticleYear
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
    Proceedings of the National Academy of Sciences of the United States of America, 2020, 12-08, Volume: 117, Issue:49

    Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection

2020
The superior efficacy of chloroquine over buparvaquone in reducing the chronic cerebral Toxoplasma gondii cysts load and improving the ultrastructural pathology in an immunocompromised murine model.
    Tropical biomedicine, 2023, Mar-01, Volume: 40, Issue:1

    Topics: Animals; Chloroquine; Cysts; Disease Models, Animal; Mice; Spiramycin; Toxoplasma; Toxoplasmosis, Animal; Toxoplasmosis, Cerebral

2023
Development of a murine vertical transmission model for Toxoplasma gondii oocyst infection and studies on the efficacy of bumped kinase inhibitor (BKI)-1294 and the naphthoquinone buparvaquone against congenital toxoplasmosis.
    The Journal of antimicrobial chemotherapy, 2017, 08-01, Volume: 72, Issue:8

    Topics: Animals; Antiprotozoal Agents; Disease Models, Animal; Female; Infectious Disease Transmission, Vertical; Male; Mice; Naphthalenes; Naphthoquinones; Piperidines; Pyrazoles; Toxoplasmosis, Animal; Toxoplasmosis, Congenital; Treatment Outcome

2017
Orally Bioavailable and Effective Buparvaquone Lipid-Based Nanomedicines for Visceral Leishmaniasis.
    Molecular pharmaceutics, 2018, 07-02, Volume: 15, Issue:7

    Topics: Administration, Oral; Animals; Antiprotozoal Agents; Biological Availability; Cell Line; Disease Models, Animal; Drug Carriers; Drug Compounding; Drug Liberation; Drug Stability; Emulsions; Excipients; Feasibility Studies; Humans; Leishmania infantum; Leishmaniasis, Visceral; Lipids; Male; Mice; Mice, Inbred BALB C; Nanoparticles; Naphthoquinones; Solubility; Treatment Outcome

2018
Effectiveness of liposomal buparvaquone in an experimental hamster model of Leishmania (L.) infantum chagasi.
    Experimental parasitology, 2012, Volume: 130, Issue:3

    Topics: Animals; Antiprotozoal Agents; Cell Line; Cells, Cultured; Cricetinae; Disease Models, Animal; Humans; Inhibitory Concentration 50; Leishmania infantum; Leishmaniasis, Visceral; Liposomes; Macaca mulatta; Macrophages, Peritoneal; Male; Mesocricetus; Mice; Mice, Inbred BALB C; Naphthoquinones; Phosphatidylserines

2012